Similar articles for PMID: 23143089

Year	Number of Results
2001	1
2002	2
2003	1
2004	4
2005	2
2006	2
2007	4
2008	1
2009	5
2010	7
2011	8
2012	11
2013	21
2014	10
2015	12
2016	4
2017	4
2019	1
2020	2
2022	4
2024	0

1

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.

Kraeber-Bodéré F, Carlier T, Naegelen VM, Shochat E, Lumbroso J, Trampal C, Nagarajah J, Chua S, Hugonnet F, Stokkel M, Gleeson F, Tessier J. Kraeber-Bodéré F, et al. J Nucl Med. 2012 Dec;53(12):1836-46. doi: 10.2967/jnumed.112.109421. Epub 2012 Nov 9. J Nucl Med. 2012. PMID: 23143089 Free article.

2

Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.

Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Fujiwara Y, Tamura Y, Wakui H, Honda K, Mizugaki H, Kitazono S, Tanabe Y, Asahina H, Yamazaki N, Suzuki S, Matsuoka M, Ogita Y, Tamura T. Nakamichi S, et al. Invest New Drugs. 2015 Jun;33(3):641-51. doi: 10.1007/s10637-015-0229-3. Epub 2015 Mar 27. Invest New Drugs. 2015. PMID: 25809858 Clinical Trial.

3

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC. Zimmer L, et al. Clin Cancer Res. 2014 Aug 15;20(16):4251-61. doi: 10.1158/1078-0432.CCR-14-0341. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947927 Clinical Trial.

4

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, Eberhardt WE. Leijen S, et al. Clin Cancer Res. 2012 Sep 1;18(17):4794-805. doi: 10.1158/1078-0432.CCR-12-0868. Epub 2012 Jul 5. Clin Cancer Res. 2012. PMID: 22767668 Clinical Trial.

5

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.

Tegnebratt T, Ruge E, Bader S, Ishii N, Aida S, Yoshimura Y, Ooi CH, Lu L, Mitsios N, Meresse V, Mulder J, Pawlak M, Venturi M, Tessier J, Stone-Elander S. Tegnebratt T, et al. EJNMMI Res. 2014 Dec;4(1):34. doi: 10.1186/s13550-014-0034-6. Epub 2014 Sep 9. EJNMMI Res. 2014. PMID: 26116108 Free PMC article.

6

18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.

Chirindel A, Chaudhry M, Blakeley JO, Wahl R. Chirindel A, et al. J Nucl Med. 2015 Mar;56(3):379-85. doi: 10.2967/jnumed.114.142372. Epub 2015 Feb 5. J Nucl Med. 2015. PMID: 25655626 Free article.

7

Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis.

Quarles van Ufford HM, van Tinteren H, Stroobants SG, Riphagen II, Hoekstra OS. Quarles van Ufford HM, et al. J Nucl Med. 2010 Oct;51(10):1507-16. doi: 10.2967/jnumed.110.075457. Epub 2010 Sep 16. J Nucl Med. 2010. PMID: 20847179 Free article.

8

18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.

Singnurkar A, Solomon SB, Gönen M, Larson SM, Schöder H. Singnurkar A, et al. J Nucl Med. 2010 Dec;51(12):1833-40. doi: 10.2967/jnumed.110.076778. Epub 2010 Nov 15. J Nucl Med. 2010. PMID: 21078787 Free article.

9

Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.

Flores LG 2nd, Yeh HH, Soghomonyan S, Young D, Bankson J, Hu Q, Alauddin M, Huff V, Gelovani JG. Flores LG 2nd, et al. Mol Imaging Biol. 2013 Apr;15(2):175-85. doi: 10.1007/s11307-012-0588-5. Mol Imaging Biol. 2013. PMID: 22875335 Free PMC article.

10

Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.

Cullinane C, Dorow DS, Jackson S, Solomon B, Bogatyreva E, Binns D, Young R, Arango ME, Christensen JG, McArthur GA, Hicks RJ. Cullinane C, et al. J Nucl Med. 2011 Aug;52(8):1261-7. doi: 10.2967/jnumed.110.086967. Epub 2011 Jul 15. J Nucl Med. 2011. PMID: 21764800 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

96 results

Results by year